Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Tapia, Gonzalo
Lundy, Joanne
Richardson, Gary Edward
Zhao, Niky
Ebsworth, Karen
Yue, Huibin
Miao, Shichang
Degoma, Emil
Jain, Rita
Schall, Thomas J.
Sullivan, Kathleen
Zhang, Penglie
De Souza, Paul L.
机构：
[1] Univ Adelaide, ICON Canc Ctr, Adelaide, SA, Australia
[2] Paso Med, Frankston, Vic, Australia
[3] Cabrini Res, Malvern, Vic, Australia
[4] ChemoCentryx, San Carlos, CA USA
[5] ChemoCentryx Inc, San Carlos, CA USA
[6] Univ Western Sydney, Sch Med, Campbelltown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2593
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
    Spigel, D. R.
    Anand, B.
    Carroll, K.
    Dekker, J.
    Georgy, A.
    Hankins, S.
    Rethy, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1102 - S1102
  • [42] A PHASE I DOSE-ESCALATION STUDY OF EMD 1214063, AN ORAL SELECTIVE CMET INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Naing, A.
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Tsimberidou, A. M.
    Wheler, J. J.
    Janku, F.
    Klevesath, M. B.
    Jego, V.
    Johne, A.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 21 - 21
  • [43] Phase Ⅰ dose-escalation and expansion study of PARP inhibitor,fluzoparib(SHR3162), in patients with advanced solid tumors
    Huiping Li
    Rongrui Liu
    Bin Shao
    Ran Ran
    Guohong Song
    Ke Wang
    Yehui Shi
    Jihong Liu
    Wenjing Hu
    Fu Chen
    Xiaoran Liu
    Gairong Zhang
    Chuanhua Zhao
    Ru Jia
    Quanren Wang
    Hope S.Rugo
    Yifan Zhang
    Guangze Li
    Jianming Xu
    Chinese Journal of Cancer Research, 2020, 32 (03) : 370 - 384
  • [44] Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
    Hong, David S.
    Kurzrock, Razelle
    Wheler, Jennifer J.
    Naing, Aung
    Falchook, Gerald S.
    Fu, Siqing
    Kim, Kevin B.
    Davies, Michael A.
    Nguyen, Ly M.
    George, Goldy C.
    Xu, Lucy
    Shumaker, Robert
    Ren, Min
    Mink, Jennifer
    Bedell, Cynthia
    Andresen, Corina
    Sachdev, Pallavi
    O'Brien, James P.
    Nemunaitis, John
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4801 - 4810
  • [45] First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
    Cooper, A.
    Andelkovic, V.
    Wilkinson, K.
    Ganju, V.
    Lundy, J.
    Hong, M.
    Airey, S.
    Meng, L. L.
    Shen, B.
    Li, H.
    Yao, L.
    Zhang, M.
    Coward, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S487 - S487
  • [46] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [47] Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
    Kyriakos P. Papadopoulos
    Eytan Ben-Ami
    Amita Patnaik
    Denise Trone
    Jianke Li
    George D. Demetri
    BMC Cancer, 18
  • [48] A phase I dose-escalation study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as continuous weekly 1-hour infusion in patients with advanced solid tumors.
    Tabernero, J
    Marimon, I
    Albanell, J
    Rojo, F
    Santomé, L
    Garcia, M
    Valverde, S
    Gadea, N
    Tuck, D
    Voi, M
    Van Vreckem, A
    Baselga, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4573S - 4573S
  • [49] Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
    Papadopoulos, Kyriakos P.
    Ben-Ami, Eytan
    Patnaik, Amita
    Trone, Denise
    Li, Jianke
    Demetri, George D.
    BMC CANCER, 2018, 18
  • [50] PHASE 1 DOSE-ESCALATION TRIAL OF THE INVESTIGATIONAL HEDGEHOG (HH) PATHWAY INHIBITOR TAK-441 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Goldman, J. W.
    Eckhardt, S. G.
    Borad, M.
    Hidalgo, M.
    Ryan, D. P.
    Parikh, A.
    Kuan, S.
    Yu, J.
    Stewart, S.
    Rosen, L. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 156 - 156
12345